The discovery of BMS-457, a potent and selective CCR1 antagonist

Bioorganic and Medicinal Chemistry Letters

Volumn 23, Issue 13, 2013, Pages 3833-3840

  Gardner, Daniel S ^a   Santella III, Joseph B ^a   Duncia, John V ^a   Carter, Percy H ^a   Dhar, T G Murali ^a   Wu, Hong ^a   Guo, Weiwei ^a   Cavallaro, Cullen ^a   Van Kirk, Katy ^a   Yarde, Melissa ^a   Briceno, Stephanie W ^a   Robert Grafstrom, R ^a   Liu, Richard ^a   Patel, Sima R ^a   Tebben, Andrew J ^a   Camac, Dan ^a   Khan, Javed ^a   Watson, Andrew ^a   Yang, Guchen ^a   Rose, Anne ^a   Foster, William R ^a   Cvijic, Mary Ellen ^a   Davies, Paul ^a   Hynes Jr , John ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

CCR1; Chemokine; Chemotaxis; PXR selectivity; Rheumatoid arthritis

Indexed keywords

BMS 457; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR1 ANTAGONIST; HYDROXYL GROUP; ION CHANNEL; PREGNANE X RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CHEMOTAXIS; DRUG POTENCY; DRUG STABILITY; HUMAN; LIPOPHILICITY; MOLECULE; NONHUMAN; SYNTHESIS;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HUMANS; MOLECULAR STRUCTURE; PIPERIDINES; RECEPTORS, CCR1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84878869013     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2013.04.079     Document Type: Article

References (51)

1. S.J. Allen, S.E. Crown, and T.M. Handel Annu. Rev. Immunol. 25 2007 787
2. R.P. Gladue, S.H. Zwillich, A.T. Clucas, and M.F. Brown Curr. Opin. Invest. Drugs 5 2004 499
3. S. Vallet, N. Raje, K. Ishitsuka, T. Hideshima, K. Podar, S. Chhetri, S. Possi, I. Breitkreutz, T. Kiziltepe, H. Yasui, E.M. Ocio, N. Shiraishi, J. Jin, Y. Okawa, H. Ikeda, S. Mukherjee, N. Vaghela, D. Cirstea, M. Ladetto, M. Boccadoro, and K.C. Anderson Blood 110 2007 3744
4. K. Furuichi, J.-L. Gao, R. Horuk, T. Wada, S. Kaneko, and P.M. Murphy J. Immunol. 181 2008 8670
5. T.J. Schall, and A.E. Proudfoot Nat. Rev. Immunol. 11 2011 355
6. A. Viola, and A.D. Luster Annu. Rev. Pharmacol. Toxicol. 48 2008 171
7. R. Horuk Nat. Rev. Drug Disc. 8 2009 23
8. J.J. Haringman, and P.P. Tak Arthritis Res. Ther. 6 2004 93
9. R. Horuk Targeting CCR1 Methods Princ. Med. Chem. 46 2011 323
10. J.-F. Cheng, and R. Jack Mol. Divers. 12 2008 17
11. For leading references to patent and public literature since that described in Ref. 6 see: P.H. Carter, and J. Hynes Expert Opin. Ther. Patents 20 2010 1609
12. J.R. Merritt, R. James, V.M. Paradkar, C. Zhang, R. Liu, J. Liu, B. Jacob, C. Chiriac, M.J. Ohlmeyer, E. Quadros, P. Wines, J. Postelnek, C.M. Hicks, W. Chen, E.F. Kimble, L. O'Brien, N. White, H. Desai, K.C. Appell, and M.L. Webb Bioorg. Med. Chem. Lett. 20 2010 5477
13. R.P. Gladue, M.F. Brown, and S.H. Zwillich Curr. Top. Med. Chem. 10 2010 1268
14. M. Liang, C. Mallari, M. Rosser, H.P. Ng, K. May, S. Monahan, J.G. Bauman, I. Islam, A. Ghannam, B. Buckman, K. Shaw, G.P. Wei, W. Xu, Z. Zhao, E. Ho, J. Shen, H. Oanh, B. Subramanyam, R. Vergona, D. Taub, L. Dunning, S. Harvey, R.M. Snider, J. Hesselgesser, M.M. Morrissey, H.D. Perez, and R. Horuk J. Biol. Chem. 275 2000 19000
15. F. Zipp, H.-P. Hartung, J. Hillert, S. Schimrigk, C. Trebst, M. Stangel, C. Infante-Duarte, P. Jakobs, C. Wolf, R. Sandbrink, C. Pohl, and M. Filippi Neurology 2006 1880 67
16. R.P. Gladue, L.A. Tylaska, W.H. Brissette, P.D. Lira, J.C. Kath, C.S. Poss, M.F. Brown, T.J. Paradis, M.J. Conklyn, K.T. Ogborne, M.A. McGlynn, B.M. Lillie, A.P. DiRico, E.N. Mairs, E.B. McElroy, W.H. Martin, I.A. Stock, R.M. Shepard, H.J. Showell, and K. Neote J. Biol. Chem. 278 2003 40473
17. J.J. Haringman, M.C. Kraan, T.J.M. Smeets, A.H. Zwinderman, and P.P. Tak Ann. Rheum. Dis. 62 2003 715
18. J. Borregaard, L. Skov, L. Wang, N. Ting, C. Wang, L.A. Beck, J. Sonne, and A. Clucas Contact Dermatitis 59 2008 212
19. C. Lu, S.K. Balani, M.G. Qian, S.R. Prakash, P.S. Ducray, and L.L. von Moltke J. Pharmacol. Exp. Ther. 332 2010 562
20. C.E. Vergunst, D.M. Gerlag, L. von Moltke, M. Karol, T. Wyant, X. Chi, E. Matzkin, T. Leach, and P.P. Tak Arthritis Rheum. 60 2009 3572
21. H.A. Kerstjens, L. Bjermer, L. Eriksson, K. Dahlstrom, and J. Vestbo Respir. Med. 104 2010 1297
22. P. Norman Expert Opin. Ther. Patents 19 2009 1629
23. M.C. Lebre, C.E. Vergunst, I.Y.K. Choi, S. Aarrass, A.S.F. Oliveira, T. Wyant, R. Horuk, K.A. Reedquist, and P.P. Tak PLoS One 6 2011 e21772
24. The structure has not been formally disclosed, but several patent applications from chemocentryx claim a single compound. For example, see: Li, L.; Pennell, A. M. K.; Zhang, P. 3-(Imidazolyl)-pyrazolo[3,4b]-pyridines, U.S. Patent application, U.S. 2010/0173911 A1.
25. D.J. Dairaghi, P. Zhang, Y. Wang, L.C. Seitz, D.A. Johnson, S. Miao, L.S. Ertl, Y. Zeng, J.P. Powers, A.M. Pennell, P. Bekker, T.J. Schall, and J.C. Jaen Clin. Pharmacol. Ther. 89 2011 726
26. CCX354 is listed in an active clinical trial on < www.clinicaltrials. gov > (accessed 8/10/11). See trial identifier NCT01242917, 'A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy (CARAT-2)'.
27. (a) Tak, P. P.; Balancescu, A.; Tseluyko, V.; Bojin, S.; Drescher, E.; Dairaghi, D.; Miao, S.; Marchesin, V.; Jaen, J.; Bekker, P.; Shall, T. J. 'Safety and Efficacy of Oral Chemokine Receptor 1 Antagonist CCX354-C in a Phase 2 Rheumatoid Arthritis Study', presentation L11, ACR/AHRP Meeting, November 8, 2011, Chicago, Illinois, USA.
28. P.P. Tak, A. Balanescu, and V. Tseluyko Ann. Rheum Dis. 2012 10.1136/annrheumdis-2011-201605
29. C.L. Cavallaro, S. Briceno, J. Chen, M.E. Cvijic, P. Davies, J. Hynes Jr., R.-Q. Liu, S. Mandlekar, A. Rose, A. Tebben, K. Van Kirk, A. Watson, H. Wu, G. Yang, and P. Carter J. Med. Chem. 55 2012 9643
30. G.V. DeLucca, U.-T. Kim, B.V. Vargo, J.V. Duncia, J.B. Santella, D.S. Gardner, C. Zheng, A. Liauw, Z. Wang, G. Emmett, D.A. Wacker, P.K. Welch, M. Covington, N.C. Stowell, E.A. Wadman, A.M. Das, P. Davies, S. Yeleswaram, D.M. Graden, K.A. Solomon, R.C. Newton, G.L. Trainor, C.P. Decicco, and S.S. Ko J. Med. Chem. 48 2005 2194
31. J.G. Varnes, D.S. Gardner, J.B. Santella, J.V. Duncia, M. Estrella, P.S. Watson, C.M. Clark, S.S. Ko, P. Welch, M. Covington, N. Stowell, E. Wadman, P. Davies, K. Solomon, R.C. Newton, G.L. Trainor, C.P. Decicco, and D.A. Wacker Bioorg. Med. Chem. Lett. 14 2004 1645
32. J.B. Santella, D.S. Gardner, W. Yao, C. Shi, P. Reddy, A. Tebben, G.V. Delucca, D.A. Wacker, P.S. Watson, P.K. Welch, E.A. Wadman, P. Davies, K.A. Solomon, D.M. Graden, S. Yeleswaram, S. Mandlekar, I. Kariv, C.P. Decicco, S.S. Ko, P.H. Carter, and J.V. Duncia Bioorg. Med. Chem. Lett. 18 2008 576
33. D.S. Gardner, J.B. Santella III, A.J. Tebben, D.G. Batt, S.S. Ko, P.K. Welch, E.A. Wadman, P. Davies, P.H. Carter, and J.V. Duncia Bioorg. Med. Chem. Lett. 18 2008 586
34. R.J. Cherney, D.J. Nelson, Y.C. Lo, G. Yang, P.A. Scherle, H. Jezak, K.A. Solomon, P.H. Carter, and C.P. Decicco Bioorg. Med. Chem. Lett. 18 2008 5063
35. R.J. Cherney, J.B. Brogan, R. Mo, Y.C. Lo, G. Yang, P.B. Miller, P.A. Scherle, B.F. Molino, P.H. Carter, and C.P. Decicco Bioorg. Med. Chem. Lett. 19 2009 597
36. R.J. Cherney, R. Mo, D.T. Meyer, M.E. Voss, Y.C. Lo, G. Yang, P.B. Miller, P.A. Scherle, A.J. Tebben, P.H. Carter, and C.P. Decicco Bioorg. Med. Chem. Lett. 19 2009 3418
37. R.J. Cherney, R. Mo, D.T. Meyer, M.E. Voss, M.G. Yang, J.B. Santella, J.V. Duncia, Y.C. Lo, G. Yang, P.B. Miller, P.A. Scherle, Q. Zhao, S. Mandlekar, M.E. Cvijic, J.C. Barrish, C.P. Decicco, and P.H. Carter Bioorg. Med. Chem. Lett. 20 2010 2425
38. M.G. Yang, Z. Xiao, Q. Shi, R.J. Cherney, A.J. Tebben, G.V. De Lucca, J.B. Santella, R. Mo, M.E. Cvijic, Q. Zhao, J.C. Barrish, and P.H. Carter Bioorg. Med. Chem. Lett. 22 2012 1384
39. P.H. Carter, G.D. Brown, S.R. King, M.E. Voss, A.J. Tebben, R.J. Cherney, S. Mandlekar, Y.C. Lo, G. Yang, P.B. Miller, P.A. Scherle, Q. Zhao, and C.P. Decicco Bioorg. Med. Chem. Lett. 22 2012 3311
40. MPTP is the acid-mediated dehydration product of MPPP. In-vivo, MPTP is metabolized to alkyl piperidinium species MPP, which destroys dopaminergic neurons in the substantia nigra of the brain, resulting in severe parkinsonism. For further reading, see J.W. Langston, and J. Palfreman The Case of the Frozen Addicts Pantheon Books 1995 ISBN 0-679-42465-2
41. S. Fahn Book Review - the case of the frozen addicts: how the solution of an extraordinary medical mystery spawned a revolution in the understanding and treatment of Parkinson's disease New Engl. J. Med. 1996 2002 335
42. L.M. Sayre, P.K. Arora, S.C. Feke, and F.L. Urbach J. Am. Chem. Soc. 108 1986 2464
43. For further reading on the topic of PXR activation, see J.M. Lehmann, D.D. McKee, M.A. Watson, T.M. Willson, J.T. Moore, and S.A. Kliewer J. Clin. Invest. 102 1998 1016
44. G. Bertilsson, J. Heidrich, K. Svensson, M. Asman, L. Jendeberg, M. Sydow-Bäckman, R. Ohlsson, H. Postlind, P. Blomquist, and A. Berkenstam Proc. Natl. Acad. Sci. U.S.A. 95 1998 12208
45. S.A. Kliewer, B. Goodwin, and T.M. Willson Endocr. Rev. 23 2002 687 and the references contained therein
46. Truncated forms of leukotactin-1 and MPIF-1 were used for the determination of chemotaxis inhibition in these assays. See T.J. Schall, R.D. Berahovich, Y.W. Miao, B. Premack, and M.C. Howard J. Immunol. 174 2005 7341
47. H.C. Brown, N.R. Ayyangar, and G. Zweifel J. Am. Chem. Soc. 86 1964 397
48. H.C. Brown, P.K. Jadhav, and M.K. Mandal Tetrahedron 37 1981 3547
49. H.C. Brown, C.M. Desai, and P.K. Jadhav J. Org. Chem. 47 1982 5065
50. H.C. Brown, and N.N. Joshi J. Org. Chem. 53 1988 4059
51. H.C. Brown, and U.P. Dhokte Tetrahedron Lett. 37 1996 9021